← Back to Search

Perfusion CT Scans for Kidney Cancer

Phase 3
Waitlist Available
Led By Chaan Ng, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects must have adequate renal function as defined by serum creatinine < 1.5x upper limit of normal.
Age >/= 18 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Study Summary

This trial will help researchers learn if DCE-CT scans can be used to see if the study drugs given in the START trial are working.

Who is the study for?
This trial is for adults over 18 with metastatic renal cell carcinoma who are enrolled or considering enrollment in the START trial. They must have good kidney function, not be pregnant or breastfeeding, and can't join if they've had recent radiotherapy to the tumor area or are allergic to CT contrast media.Check my eligibility
What is being tested?
The study tests whether a special type of CT scan called dynamic contrast enhanced computed tomography (DCE-CT) can determine how well treatments like everolimus, bevacizumab, or pazopanib are working in patients with advanced kidney cancer.See study design
What are the potential side effects?
Potential side effects may include reactions to the CT contrast agent used during scans such as mild allergic reactions, nausea, vomiting, itching or hives. Serious side effects are rare but could involve kidney issues due to the contrast material.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney function is within the normal range.
Select...
I am 18 years old or older.
Select...
My cancer is advanced kidney cancer that has spread.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Tumor Blood Flow (BF) Reduction
Secondary outcome measures
Progression Free Survival (PFS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: DCE-CT ScansExperimental Treatment1 Intervention
DCE-CT = Dynamic contrast enhanced CT - DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perfusion CT scan
2019
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,966 Previous Clinical Trials
1,804,661 Total Patients Enrolled
Chaan Ng, MDPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
178 Total Patients Enrolled

Media Library

Perfusion CT scan Clinical Trial Eligibility Overview. Trial Name: NCT01224288 — Phase 3
Kidney Cancer Research Study Groups: DCE-CT Scans
Kidney Cancer Clinical Trial 2023: Perfusion CT scan Highlights & Side Effects. Trial Name: NCT01224288 — Phase 3
Perfusion CT scan 2023 Treatment Timeline for Medical Study. Trial Name: NCT01224288 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the FDA condone Perfusion CT scanning?

"Given that this is a Phase 3 trial with supporting efficacy data and rounds of safety data, our team has given Perfusion CT scan a 3 for safety."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
2011. "Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01224288.
All > Metastatic Renal Cell Carcinoma > Renal Cell Carcinoma
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top